Findings

What do systematic reviews say?

108 questions · 108 findings · 14 reviews · Skin

Sort:Best matchNewest Highest certainty Download CSV

No studies found 20 · 18.5%GRADE not reported 4 · 3.7%Very low 34 · 31.5%Low 25 · 23.1%Moderate 24 · 22.2%High 1 · 0.9%

Prednisone plus azathioprine vs prednisone

Adverse events · bullous pemphigoid

1 finding from 1 review

Interventions for bullous pemphigoid 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Very low

Nicotinamide plus tetracycline vs prednisone

Adverse events at 1 year · bullous pemphigoid

1 finding from 1 review

Interventions for bullous pemphigoid 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Very low

Methylprednisolone plus azathioprine vs methylprednisolone plus dapsone

Adverse events at 1 year · bullous pemphigoid

1 finding from 1 review

Interventions for bullous pemphigoid 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Very low

Mild clobetasol propionate cream regimen (10 to 30 g/day) vs standard clobetasol propionate cream regimen (40 g/day)

Adverse events at 1 year · bullous pemphigoid

Mild clobetasol propionate cream regimen (10 to 30 g/day) showed no clear difference in adverse events at 1 year compared with standard clobetasol propionate cream regimen (40 g/day) (low certainty).

1 finding from 1 review

Interventions for bullous pemphigoid 2023 · Cochrane Headline outcomes only
RR 0.94 [0.78, 1.14]
1 study · 309 participants
Low

Oral hydroxychloroquine vs placebo

Adverse events: severe · patients with cutaneous disease in systemic lupus erythematosus

Oral hydroxychloroquine showed no clear difference in adverse events: severe compared with placebo (moderate certainty).

1 finding from 1 review

Interventions for cutaneous disease in systemic lupus erythematosus 2021 · Cochrane Headline outcomes only
RR 3.9 [0.19, 78.46]
1 study · 71 participants
Moderate

Oral hydroxychloroquine vs placebo

Minor adverse events · patients with cutaneous disease in systemic lupus erythematosus

Oral hydroxychloroquine showed no clear difference in adverse events: minor compared with placebo (moderate certainty).

1 finding from 1 review

Interventions for cutaneous disease in systemic lupus erythematosus 2021 · Cochrane Headline outcomes only
RR 1.32 [0.24, 7.19]
1 study · 47 participants
Moderate

Oral dehydroepiandrosterone vs placebo

Adverse events: severe · patients with cutaneous disease in systemic lupus erythematosus

Oral dehydroepiandrosterone showed no clear difference in adverse events: severe compared with placebo (moderate certainty).

1 finding from 1 review

Interventions for cutaneous disease in systemic lupus erythematosus 2021 · Cochrane Headline outcomes only
RR 0.09 [0.01, 1.66]
1 study · 381 participants
Moderate

Oral dehydroepiandrosterone vs placebo

Minor adverse events · patients with cutaneous disease in systemic lupus erythematosus

Oral dehydroepiandrosterone probably leads to higher adverse events: minor compared with placebo (moderate certainty).

1 finding from 1 review

Interventions for cutaneous disease in systemic lupus erythematosus 2021 · Cochrane Headline outcomes only
RR 10.5 [3.26, 33.75]
1 study · 381 participants
Moderate

Oral chloroquine vs placebo

Adverse events: severe · patients with cutaneous disease in systemic lupus erythematosus

Oral chloroquine showed no clear difference in adverse events: severe compared with placebo (low certainty).

1 finding from 1 review

Interventions for cutaneous disease in systemic lupus erythematosus 2021 · Cochrane Headline outcomes only
RR 0.33 [0.01, 7.45]
1 study · 24 participants
Low

Oral chloroquine vs placebo

Minor adverse events · patients with cutaneous disease in systemic lupus erythematosus

1 finding from 1 review

Interventions for cutaneous disease in systemic lupus erythematosus 2021 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Oral ciclosporin vs azathioprine (AZA)

Adverse events: severe · patients with cutaneous disease in systemic lupus erythematosus

Oral ciclosporin showed no clear difference in adverse events: severe compared with oral azathioprine (low certainty).

1 finding from 1 review

Interventions for cutaneous disease in systemic lupus erythematosus 2021 · Cochrane Headline outcomes only
RR 0.89 [0.48, 1.65]
1 study · 89 participants
Low

Oral methotrexate vs oral chloroquine

Adverse events: severe · patients with cutaneous disease in systemic lupus erythematosus

Oral methotrexate showed no clear difference in adverse events: severe compared with oral chloroquine (low certainty).

1 finding from 1 review

Interventions for cutaneous disease in systemic lupus erythematosus 2021 · Cochrane Headline outcomes only
RR 1.73 [0.27, 11.07]
1 study · 41 participants
Low

Oral methotrexate vs oral chloroquine

Minor adverse events · patients with cutaneous disease in systemic lupus erythematosus

Oral methotrexate may leads to higher adverse events: minor compared with oral chloroquine (low certainty).

1 finding from 1 review

Interventions for cutaneous disease in systemic lupus erythematosus 2021 · Cochrane Headline outcomes only
RR 3.9 [1.45, 10.51]
1 study · 41 participants
Low

Oral methotrexate vs placebo

Adverse events: severe · patients with cutaneous disease in systemic lupus erythematosus

Oral methotrexate showed no clear difference in adverse events: severe compared with placebo (moderate certainty).

1 finding from 1 review

Interventions for cutaneous disease in systemic lupus erythematosus 2021 · Cochrane Headline outcomes only
RR 12.05 [0.69, 211.36]
1 study · 86 participants
Moderate

Oral methotrexate vs placebo

Minor adverse events · patients with cutaneous disease in systemic lupus erythematosus

Oral methotrexate showed no clear difference in adverse events: minor compared with placebo (moderate certainty).

1 finding from 1 review

Interventions for cutaneous disease in systemic lupus erythematosus 2021 · Cochrane Headline outcomes only
RR 0.68 [0.39, 1.17]
1 study · 86 participants
Moderate

Serlopitant 0.25 mg vs placebo

Adverse events · chronic pruritus of unknown origin

It is very uncertain whether serlopitant 0.25 mg changes adverse events compared with placebo (very low certainty).

1 finding from 1 review

Interventions for chronic pruritus of unknown origin 2020 · Cochrane Headline outcomes only
RR 1.29 [0.75, 2.24]
1 study · 127 participants
Very low

Serlopitant 5 mg vs placebo

Adverse events · chronic pruritus of unknown origin

It is very uncertain whether serlopitant 5 mg changes adverse events compared with placebo (very low certainty).

1 finding from 1 review

Interventions for chronic pruritus of unknown origin 2020 · Cochrane Headline outcomes only
RR 1.48 [0.87, 2.5]
1 study · 127 participants
Very low

Serlopitant 1 mg vs placebo

Adverse events · chronic pruritus of unknown origin

It is very uncertain whether serlopitant 1 mg changes adverse events compared with placebo (very low certainty).

1 finding from 1 review

Interventions for chronic pruritus of unknown origin 2020 · Cochrane Headline outcomes only
RR 1.45 [0.86, 2.47]
1 study · 128 participants
Very low

Tacrolimus 0.1% vs mometasone furoate ointment

Primary outcome 3: Adverse events · people with moderate to severe chronic relapsing dyshidrotic eczema on hands

1 finding from 1 review

Interventions for hand eczema 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 16 participants
Moderate

Oral retinoids: alitretinoin 10 mg vs placebo

Primary outcome 3: Adverse events · people with moderate to severe chronic hand eczema

Oral retinoids: alitretinoin 10 mg showed no clear difference in primary: all adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Interventions for hand eczema 2019 · Cochrane Headline outcomes only
RR 1.01 [0.66, 1.55]
1 study · 158 participants
Moderate